Triple

T391439
Position Surface form Disambiguated ID Type / Status
Subject Johnson & Johnson E8888 entity
Predicate notableProduct P1448 FINISHED
Object Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
 E49853 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Darzalex | Statement: [Johnson & Johnson, notableProduct, Darzalex]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Darzalex
Context triple: [Johnson & Johnson, notableProduct, Darzalex]
  • A. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • B. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • C. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • D. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • E. Plegridy
    Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Darzalex
Triple: [Johnson & Johnson, notableProduct, Darzalex]
Generated description
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Darzalex
Target entity description: Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • A. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • B. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • C. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • D. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • E. Plegridy
    Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a2e7f55c60819097aff65ea2ca2832 completed Feb. 28, 2026, 1:04 p.m.
NER Named-entity recognition batch_69a2ec5d73e881909101308a583c8f13 completed Feb. 28, 2026, 1:23 p.m.
NED1 Entity disambiguation (via context triple) batch_69a405f74cd08190a2e165506638607c completed March 1, 2026, 9:25 a.m.
NEDg Description generation batch_69a406a17fdc8190a067217b806fbc57 completed March 1, 2026, 9:28 a.m.
NED2 Entity disambiguation (via description) batch_69a4070050dc81909fdfbcfce23e428e completed March 1, 2026, 9:29 a.m.
Created at: Feb. 28, 2026, 1:08 p.m.